spacer
home > ebr > winter 2020 > why the regulation of cbd isn’t abc
PUBLICATIONS
European Biopharmaceutical Review

Why the Regulation of CBD Isn’t ABC




There are not many things you can guarantee in life, but I guarantee that:
1. By the time you read this article it will be out of date
2. The regulations for cannabis-derived products will have changed

So why are there such rapid changes impacting the EU cannabis market? To answer this question we need to examine some history.

One of the earliest recorded medicinal uses of Cannabis sativa in Europe was in Nicholas Culpeper’s The Complete Herbal published in 1649 (1). Among the plant’s many ‘medicinal virtues’, he states that a “decoction of the root eases gouty pains, hard knots in the joints and pain in the sinews and hips”. The 1983 publication of The Complete Herbal includes ‘modern uses’ stating that “cannabis is an analgesic and hallucinatory drug. It is smoked like opium in many eastern countries and illegally in the West. It is anti-spasmodic and will reduce nerve pain, but it has toxic side-effects”. Between 1649 and 1983, cannabis became classified as a ‘controlled drug’ under the UK’s Misuse of Drugs Act 1971, and, therefore, became illegal. At around the same time, cannabis also became illegal in many other territories.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Greer Deal has over 25 years’ experience in the life sciences sector and, in October 2007, she realised Bobby Deal’s vision to establish an independent consultancy, Global Regulatory Services (GRS), with a focus on regulatory affairs and quality compliance. Her experience includes regulatory affairs, medical information, pharmacovigilance, product development, compassionate use programmes ‘specials’, and plant derived products. She frequently speaks at seminars across the globe. Greer is also a fellow of the Chartered Management Institute and a member of The Organisation for Professionals in Regulatory Affairs (TOPRA).
spacer
Greer Deal
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers
 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement